Edgewise Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.455
- Today's High:
- $6.64
- Open Price:
- $6.64
- 52W Low:
- $5.53
- 52W High:
- $14.33
- Prev. Close:
- $6.54
- Volume:
- 75213
Company Statistics
- Market Cap.:
- $594.19 million
- Book Value:
- 5.197
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -16.66%
- Return on Equity TTM:
- -25.74%
Company Profile
Edgewise Therapeutics Inc had its IPO on 2021-03-26 under the ticker symbol EWTX.
The company operates in the Healthcare sector and Biotechnology industry. Edgewise Therapeutics Inc has a staff strength of 67 employees.
Stock update
Shares of Edgewise Therapeutics Inc opened at $6.64 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.46 - $6.64, and closed at $6.58.
This is a +0.61% increase from the previous day's closing price.
A total volume of 75,213 shares were traded at the close of the day’s session.
In the last one week, shares of Edgewise Therapeutics Inc have increased by +2.02%.
Edgewise Therapeutics Inc's Key Ratios
Edgewise Therapeutics Inc has a market cap of $594.19 million, indicating a price to book ratio of 1.3626 and a price to sales ratio of 0.
In the last 12-months Edgewise Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-82056000. The EBITDA ratio measures Edgewise Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Edgewise Therapeutics Inc’s operating margin was 0% while its return on assets stood at -16.66% with a return of equity of -25.74%.
In Q1, Edgewise Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Edgewise Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Edgewise Therapeutics Inc’s profitability.
Edgewise Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.1054. Its price to sales ratio in the trailing 12-months stood at 0.
Edgewise Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $346.40 million
- Total Liabilities
- $12.72 million
- Operating Cash Flow
- $49.04 million
- Capital Expenditure
- $4.37 million
- Dividend Payout Ratio
- 0%
Edgewise Therapeutics Inc ended 2024 with $346.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $346.40 million while shareholder equity stood at $328.84 million.
Edgewise Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $12.72 million in other current liabilities, 6000.00 in common stock, $-167438000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.23 million and cash and short-term investments were $327.95 million. The company’s total short-term debt was $797,000 while long-term debt stood at $0.
Edgewise Therapeutics Inc’s total current assets stands at $327.95 million while long-term investments were $0 and short-term investments were $279.72 million. Its net receivables were $251000.00 compared to accounts payable of $3.88 million and inventory worth $0.
In 2024, Edgewise Therapeutics Inc's operating cash flow was $49.04 million while its capital expenditure stood at $4.37 million.
Comparatively, Edgewise Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.58
- 52-Week High
- $14.33
- 52-Week Low
- $5.53
- Analyst Target Price
- $23.4
Edgewise Therapeutics Inc stock is currently trading at $6.58 per share. It touched a 52-week high of $14.33 and a 52-week low of $14.33. Analysts tracking the stock have a 12-month average target price of $23.4.
Its 50-day moving average was $6.96 and 200-day moving average was $8.34 The short ratio stood at 22.93 indicating a short percent outstanding of 0%.
Around 90.6% of the company’s stock are held by insiders while 10714.1% are held by institutions.
Frequently Asked Questions About Edgewise Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.